Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on the Pharmacokinetics of HRS-4642 in Healthy Participants
NCT07906691Phase 1Not yet recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-4642 in pancreatic cancer (PC), sponsored by Hengrui Therapeutics. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time 0 to Last Quantifiable Concentration and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07906691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906691.